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Rapid and simple routes to functional polymersomes are increasingly needed to expand their clinical or industrial 
applications. Here we describe a novel strategy where polymersomes are prepared through an in-line process in 
just a few hours, starting from simple acrylate or acrylamide monomers. Using Perrier’s protocol, well-defined 
amphiphlic diblock copolymers formed from PEG acrylate (mPEGA480), 2-(acryloyloxy)ethyl-3-chloro-4-
hydroxybenzoate (ACH) or 2-(3-chloro-4-hydroxybenzamido)ethyl acrylate (CHB), have been synthesised by RAFT 
polymerisation in one-pot, pushing the monomer conversion for each block close to completion (≥94%). The 
reaction mixture, consisting of green biocompatible solvents (ethanol/water) have then been directly utilised to 
generate well-defined polymersomes, by simple cannulation into water or in a more automated process, by using 
a bespoke microfluidic device. Terbinafine and cyanocobalamine were used to demonstrate the suitability of the 
process to incorporate model hydrophobic and hydrophilic drugs, respectively. Vesicles size and morphology were 
characterised dy DLS, TEM, and AFM. In this work we show that materials and experimental conditions can be 
chosen to allow facile and rapid generation drug-loaded polymersomes, through a suitable in-line process, directly 
from acrylate or acrylamide monomer building blocks.  
Introduction 
Polymersomes1 are vesicular assemblies formed from amphiphilic block copolymers, which have rapidly 
emerged as an important class of nanomaterials, with range of potential applications which include drug 
delivery, diagnostics and bioimaging.2, 3, 4 To date, polymersomes have been the subject of over 500 papers, 
  
with at least 11 patents filed within the last two years.5 Compared to phospholipid vesicles, polymersomes 
typically possess improved membrane stability, as well as superior tuneability of surface chemistry and 
structural parameters.6  
An increasingly large area of research is focussed on the use of polymersomes as drug nanovectors in drug 
delivery.7-10 Recently, Battaglia and coworkers showed delivery of an IgG model cargo to the Central 
Nervous System (CNS) parenchyma and CNS cells mediated by poly(2-diisopropylamino)ethyl 
methacrylate)-based pH-responsive polymersomes functionalized with LRP-1-targeting Angiopep-2 and 
Rabies Virus Glycoprotein (RVG) peptide ligands to facilitate transport through the blood-brain barrier.11  
Polymersomes have also been utilised to create nanosized reactors, where entrapped (bio)molecules – e.g. 
enzymes – are part of multicompartmental arrangements mimicking those found in cell organelles. In an 
early work Meier and coworkers incorporated β-lactamase within PDMS-PMOXA triblock copolymer 
vesicles.12 The introduction of a channel-forming protein from the outer cell wall of Gram-negative bacteria 
(OmpF) into the vesicle membrane allowed passive transport of ampicillin, an enzyme substrate, which 
was converted in the polymersome aqueous lumen into ampicillinoic acid. Lecommandoux and van Hest 
engineered multicompartimentalised polymersomes-in-polymersomes systems, mimicking artificial cells 
and cell organelles.13 These studies, in conjunction with the potential for self-propulsion,14 make 
polymersomes ideal candidates for the development of polymeric protocells.15 16  
In terms of their manufacturing, polymersomes are often assembled from amphiphilic block copolymers 
synthesised through long synthetic procedures - typically at least two sequential polymerisations, requiring 
purification of both polymer intermediates and final amphiphilic macromolecules from unreacted 
monomers and traces of other low molecular weight impurities. Importantly, polymerisation reactions 
often need to be stopped at moderate monomer conversions to ensure high proportion of chain-end 
fidelity, which is required for subsequent polymer chain-extension.17-19 
 
   
 
Chart 1 In line engineering of mPEGA12a-b-ACH36 or mPEGA12a-b-CHB36 polymeric vesicles via one-pot RAFT and in 
line post-polymerisation assembly. 
In addition to being not fully efficient, this approach invariably results in waste of functional monomers 
utilised for the polymerisation step, which is undesirable especially when these are particularly expensive, 
not commercially available, or both. Finally, the processes for the assembly of polymersomes are not 
always trivial.20 Although a range of techniques have been developed,21 most methods still suffer from low 
reproducibility and poor scalability, which may complicate industrial application of polymersomes.6 Whilst 
chemists are increasingly focussing on developing more efficient and greener chemical transformations – 
i.e. as described by Sharpless and coworkers’ click chemistry philosophy – one could envisage that 
analogous approaches could be applied not only to individual chemical reactions, but also to entire 
processes. A clear move in this direction is the work on polymerization-induced self-assembly (PISA) by 
Armes’ group and others,22-30 where block copolymers nano-objects can be assembled with predictable 
shape and size during the polymerisation process, by judicious choice of monomers and variation of 
polymer physicochemical characteristics (e.g. packing parameter P).31  
In the present work we aimed to develop a route to self-assembled drug nanovectors which would 
complement the range of applications inherent to PISA. In this case, drug-loaded nanovesicles are 
engineered by sequential and quantitative polymerisation of appropriate monomers in one pot, followed 
by self-assembly of the resulting amphiphilic block copolymers into vesicles, by directly adding the final 
reaction mixture to a suitable aqueous phase (Chart1). Key advantages of this approach include the 
avoidance of intrinsically inefficient purifications of polymer intermediates, the potential for incorporating 
a wide range of drugs – including those not compatible with radical polymerisation conditions, and, 
similarly to PISA, facile assembly of nanovectors directly from the polymerisation solution, but without 
having to remove excess unreacted monomers.  
  
For the polymerisation step, recent studies by Perrier and co-workers showed that well-defined multiblock 
copolymers can be obtained by RAFT polymerisation in one pot by sequential and quantitative 
polymerisation of suitable monomers in only a few hours18, 32, 33 or even minutes.34  The monomers were 
selected based on previous studies, where we showed that block copolymers based on novel pH-responsive 
monomers bearing substituted aromatic alcohols could be effectively assembled into well-defined 
nanovesicles, whilst incorporating specific drugs with high efficiency.35, 36  
Experimental 
Materials 
Terbinafine free base was extracted from a basic aqueous solution of terbinafine hydrochloride (Sigma-
Aldrich ≥ 98%) with dichloromethane (see ESI). VA-044 was purchased from Wako Pure Chemical Industries 
Ldt.  All the other solvents and reagents were purchased from Sigma-Aldrich or Fisher Scientific and used 
as received. Spectra/Por 8 kDa MWCO and SnakeSkin 3.5 kDa MWCO dialysis tubing were obtained from 
Fisher Scientific and VWR International, respectively. Cellulose membranes (0.45 and 0.22 μm) were 
purchased from Merck Millipore. 1H-13C HSQC NMR experiments were carried out to facilitate peaks 
assignment. Yields were not optimized.  
 
Synthesis of 2-(acryloyloxy)ethyl 3-chloro-4-hydroxybenzoate (ACH, 2) and 2-(3-chloro-4-
hydroxybenzamido)ethyl acrylate (CHB, 3). The synthesis of the acrylic ACH (2) and acrylamide CHB (3) 
monomers was carried out by reaction of 3-chloro-4-hydroxybenzoic acid with 2-hydroxyethyl acrylate 
(HEA) or N-hydroxyethyl acrylamide (HEAM), respectively. The typical procedure is described here for the 
synthesis of ACH (2) monomer. A solution of DCC (17.1 g, 82.7 mmol) in anhydrous CH2Cl2 (100 mL) was 
added dropwise and under stirring to a solution of 3-chloro-4-hydroxybenzoic acid (10.0 g, 55.1 mmol) and 
DMAP (0.256 g, 2.09 mmol) dissolved in 2-hydroxyethyl acrylate (63.3 mL, 551 mmol), over 30 minutes The 
reaction mixture was stirred at room temperature for 16 hours, and the resulting dicyclohexylurea (DCU) 
precipitate was removed by filtration. The solvent was removed under reduced pressure, the resulting 
residue dissolved in MeOH, and the monomer precipitated in deionized water at pH 5.0 to remove most of 
the excess of HEA. The precipitate was isolated by centrifugation, redissolved in CH2Cl2 (ca. 150 mL) and 
the resulting solution was dried over MgSO4, filtered, and the solvent removed under reduced pressure. 
The crude product was purified by flash chromatography (silicagel 60, 35-70 µm, CH2Cl2/EtOAc 9.5:0.5 
vol/vol). Evaporation of the solvent from the relevant fractions yielded the desired monomer  ACH (2) as a 
white solid. CHB (3) was synthesised using THF instead of  CH2Cl2 as the solvent and was purified by flash 
chromatography (silicagel 60, 35-70 µm, eluents  CH2Cl2/EtOAc, gradient 9.5:0.5 to 1:1, vol/vol). 
   
ACH (2): 13.6 g, 50.1 mmol. Yield: 90.9%. ESI-TOF mass spectrometry: expected m/z for [M-H]- 269.02, 
found 269.02 Da FT-IR: ν 3330, 2937, 1716, 1686, 1601, 1580, 1455, 1411, 1363, 1251, 1186, 1072, 1023, 
966, 936, 897, 833, 810, 760, 709 cm-1. 1H NMR (400 MHz, CDCl3, δ, ppm): 4.47-4.55 (m, 4H, CH2), 5.88 (dd, 
J = 10.4, 1.4 Hz, 1H, CH=CHH), 6.14 (dd, J = 17.3, 10.4 Hz, 1H, CH=CH2), 6.42 (dd, J = 17.3, 1.4 Hz, 1H, 
CH=CHH), 7.07 (d, J = 8.6 Hz, 1H, CH aromatic), 7.9 (dd, J= 8.5, 2.0 Hz, 1H, CH aromatic), 8.03 (d, J = 2.0 Hz, 
1H, CH aromatic). 13C {1H} NMR (100 MHz, CDCl3, δ, ppm): 62.43 (1C, CH2O), 63.00 (1C, CH2O), 116.24 (1C, 
C aromatic), 120.23 (1C, C aromatic), 123.29 (1C, C aromatic), 128.08 (1C, CH=CH2), 130.52 (1C, C aromatic, 
CH), 131.21 (1C, C aromatic), 131.65 (1C, CH2=CH), 155.76 (1C, C aromatic), 165.13 (1C, C=O), 166.03 (1C, 
C=O). 
CHB (3). 3.00 g, 11.2 mmol, Yield: 40.7 %. ESI-TOF mass spectrometry: expected m/z for [M-H]- 268.04, 
found 267.92 Da FT-IR: ν 3328, 3139, 2938, 2111, 1690, 1646, 1617, 1596, 1527, 1489, 1386, 1357, 1323, 
1294, 1265, 1238, 1145, 1118, 1053, 972, 890, 872, 834, 804, 669 cm-1. 1H NMR (400 MHz, MeOD, δ, ppm): 
3.64 (t, J = 5.4 Hz, 2H, CH2N), 4.36 (t, J = 5.4 Hz, 2H, OCH2), 5.66 (dd, 1H, J = 8.3, 3.7 Hz , 1H, CH=CHH, 6.22 
(dd, 1H, J = 17.1, 3.7, Hz, CH=CHH), 6.27 (dd, 1H, J = 17.1, 8.3, Hz, CH=CH2), 6.95 (d, 1H, J = 8.5 Hz, CH 
aromatic), 7.82 (m, 1H, CH aromatic), 7.98 (m, 1H, CH aromatic). 13C {1H} NMR (100 MHz, MeOD, δ ppm): 
39.55 (1C, CH2NH), 64.51 (1C, CH2O), 117.1 (1C, C aromatic, CH), 121.8 (1C, C aromatic, CCl), 123.18 (1C, C 
aromatic, CCO), 126.96 (1C, CH2=C), 130.95 (1C, C aromatic, CH), 131.83, (1C, CH=CH2),  132.79 (1C, C 
aromatic, CH), 159.16 (1C, C aromatic, C-OH), 166.83 (1C, C=O), 168.45 (1C, C=O). 
General one-pot polymerisation procedure: synthesis of mPEGA12a-b-ACH36 (6), block copolymers  
The synthesis of the pH-responsive block copolymers was performed via an adaptation of the one-pot RAFT 
polymerisation strategy described by Perrier and co-workers.18 Monomer conversion after each step are 
shown in Table 1. 
mPEGA12a-b-ACH36. mPEGA(480) (440 µL, 1.00 mmol) and MHP RAFT Agent (19.9 mg, 83.3 µmol, synthesis 
and characterisation are reported in the supporting information) were placed in a tube equipped with a 
magnetic follower and EtOH (100 µL) was added (NOTE: the monomer:solvent vol:vol ratio was found to 
be critical to achieve the required degree of control over the chain end-group fidelity, in agreement with 
what described by Perrier and co-workers.18, 32-34 Here a 2.0 M monomer concentration was used in all 
cases, and when liquid monomers were used, their volume was taken into account when calculating the 
solvent required to achieve the required monomer concentration). The tube was sealed with a rubber 
septum, placed in an ice bath, stirred for 5 min to allow temperature equilibration, deoxygenated by gentle 
Argon bubbling for 15 minutes, and finally placed in an oil bath pre-heated at 70°C. 0.332 µmol of VA-044 
(59 µL of a 1.82 mg mL-1 deoxygenated stock solution in HPLC-grade water) were then added via gas-tight 
syringe to the reaction tube (t0). After 2 h near-quantitative conversion of mPEGA(480) into mPEGA12a 
  
macro-CTA was confirmed by 1H NMR of an aliquot taken from the reaction mixture, which was also 
analysed by SEC (DMF + 0.1% LiBr as the mobile phase) to estimate Mn and polydispersity index of the 
mPEGA12a polymer intermediate.  
In a separate Schlenk tube ACH monomer (803 mg, 2.96 mmol) was dissolved in 1.5 mL of water:EtOH (1:2 
vol/vol); the tube was placed in an ice bath, stirred for 5 min to allow temperature equilibration, and 
deoxygenated by gentle Argon bubbling for 15 minutes. This solution was then cannulated under Argon 
into the polymerisation tube containing mPEG12a macro-CTA, and the resulting solution heated at 70°C 
under stirring. The polymerisation was started by addition of a previously degassed VA-044 solution in 
HPLC-grade water (96 µL, 0.54 µmol) via gas-tight syringe. After 2 h at 70°C ACH monomer conversion was 
checked by 1H NMR in DMSO-d6. Three sequential additions of degassed fresh initiator solution (96 µL), 
each followed by 2 h stiring at 70°C were performed, until conversion finally reached 94%. 
mPEGA12b-b-CHB36 (7): the synthesis of mPEGA12b-b-CHB36 block copolymer was performed as described 
above, but five sequential additions of degassed VA-044  initiator solution (96 µL, 0.54 µmol) were 
performed to reach 99% monomer conversion. 
mPEGA12a (4): conversion = 95% Mn, theor = 5.71 kDa; DP theor = 11.4, Mn (GPC, DMF) = 6.49 kDa; Đ(GPC, DMF)  = 1.05 
mPEGA12b (5): conversion = 97% Mn, theor = 5.83 kDa; Mn (GPC, CHCl3) = 5.3 kDa; DP = 11.6; Đ(GPC, CHCl3) = 1.13. 
mPEGA12a-b-ACH36 (6): conversion = 94%; Mn, theor  = 14.92 kDa; Mn (GPC, DMF) = 14.9 kDa; DP 2nd block = 36; 
Đ(GPC, DMF) = 1.18 
mPEGA12b-b-CHB36 (7): conversion = 99%; Mn, theor = 14.97 kDa; Mn (GPC, DMF) = 15.07 kDa; DP theor 2nd block = 
36; Đ(GPC, DMF) = 1.17. 
In line assembly of polymersomes 
In a typical procedure, at the end of the polymerisation run the reaction mixture was diluted with EtOH to 
a final polymer concentration of 35 mg mL-1 while maintaining the temperature at 40°C, under stirring. The 
resulting polymer solution was then directly cannulated into DI water (EtOH:H2O 1:35 vol/vol, final polymer 
concentration 1.0 mg mL-1). 
The polymersomes formation occurred instantaneously, as confirmed by DLS. To remove the residual 
ethanol, the vesicles suspension was transferred into a dialysis bag (3.5 kDa MWCO) and dialyzed against 
5 L of DI water for 4 hours at room temperature with at least 4 water exchanges. Alternatively, the beaker 
containing the polymersomes suspensions were left to stir overnight to allow the organic solvent to 
evaporate. Samples were analysed by DLS and TEM. 
Polymersomes assembly by nanoprecipitation 
For comparative purposes, assembly of polymersomes was also performed by nanoprecipitation on 
purified block copolymers. Briefly, at the end of the polymerisation reaction mixtures were diluted with 
   
acetone (10 mL) and precipitated twice in petroleum ether (200 mL). 5 mg mL-1 polymer solutions were 
then prepared in DMSO, and diluted to 1 mg mL-1 by addition of either water or PBS.  To remove the organic 
solvent, vesicles suspensions were transferred into a dialysis bag (3.5 kDa MWCO) and dialyzed against 5 L 
of DI water or PBS for 24 hours at room temperature with at least 4 solvent exchanges. Vesicles size was 
analysed by DLS and, for samples prepared in PBS, by atomic force microscopy (AFM).  
Polymersome assembly via a microfluidic device 
Polymersomes were also assembled using a bespoke microfluidic device. Two syringes feeding into the 
device were driven simultaneously by a dual Cole-Palmer 789210C syringe pump. A 10 mL syringe (internal 
diameter 15.8 mm) delivered at 12 times the volume flow rate of the 1 mL syringe (internal diameter 4.6 
mm). The 1 mL syringe was maintained at 50°C by a heating jacket and contained an ethanolic solution (12 
mg mL-1) of mPEGA12b-b-CHB36. This solution was injected into the device at a flow rate of 10 µL min-1 (Flow 
A, fig 4), via a 27G needle (internal diameter 0.21 mm) inserted into a PTFE tube (ID 0.5 mm). The tube 
ensured a leak-free fit while allowing the needle to be removed as required. Concurrently, water was 
introduced in the device via the 10 mL syringe, through another ID 0.5 mm PTFE tube, at a flow rate of 120 
µL min-1 (Flow B, fig 4). The tubes led to a mixing junction placed on a 60°C hotplate, and the mixed flow 
(Flow C, 130 µL min-1, fig 4) excited the device to a collection vial via an ID 1 mm tube. The experiment was 
repeated twice and at least 3 different samples were collected and analysed by DLS. 
Drug loading procedure. 
Terbinafine free base and cyanocobalamin co-loaded polymersomes were assembled following a 
procedure analogous to that described in the “in line assembly of polymersomes” section. Typically, 
terbinafine free base (10% w/w drug/polymer) and cyanocobalamin (10% w/w drug/polymer) were 
respectively added to the polymer ethanolic/water solution and/or the aqueous phase before the assembly 
procedure. To remove unentrapped cyanocobalamin and residual organic solvent the polymersomes 
suspension was dialysed with 8 kDa MWCO dialysis membrane against 5 L of DI water, with 4 water 
exchanges in 5 hours. Unentrapped terbinafine, precipitated after dialysis, was removed by centrifugation 
(1500 rpm, 5 minutes) followed by filtration through a 0.45 µm mixed cellulose ester membrane. 
Drug loading was then quantified via a RP-HPLC method (see ESI). Loading reported for each polymer is the 
average of two independent experiments, each prepared and analysed in triplicate.  
Loading Capacity (LC) and Encapsulation Efficiency (EE) were calculated as: 
𝑳𝑪 =  
𝑨𝒎𝒐𝒖𝒏𝒕 𝒐𝒇 𝒍𝒐𝒂𝒅𝒆𝒅 𝒅𝒓𝒖𝒈
𝑨𝒎𝒐𝒖𝒏𝒕 𝒐𝒇 𝒑𝒐𝒍𝒚𝒎𝒆𝒓
 𝒙 𝟏𝟎𝟎 
  
𝑬𝑬 =  
𝑨𝒎𝒐𝒖𝒏𝒕 𝒐𝒇 𝒍𝒐𝒂𝒅𝒆𝒅 𝒅𝒓𝒖𝒈
𝑻𝒐𝒕𝒂𝒍 𝒂𝒎𝒐𝒖𝒏𝒕 𝒐𝒇 𝒅𝒓𝒖𝒈
 𝒙 𝟏𝟎𝟎 
Polymersome size analysis 
Particles size analyses were carried out at 25ºC by Dynamic Light Scattering (DLS) using a Zetasizer Nano 
spectrometer (Malvern Instruments Ltd) equipped with a 633 nm laser at a fixed angle of 173°. Samples 
were kept at constant temperature (25 ° C) during all the experiments. Polymeric vesicles were prepared 
as described in “in line assembly of polymersomes”, by nanoprecipitation or via microfluidic device. 
Residual EtOH was removed either by solvent evaporation or by dialysis with a 3.5 kDa MWCO dialysis 
membrane before analysis. Results are reported as the z-average. All experiments were performed in 
triplicate. 
Transmission Electron Microscopy (TEM)  
Transmission Electron Microscopy (TEM) was performed on a FEI TecnaiTM 12 Biotwin transmission 
electron microscope. 20 µL of 1 mg mL-1 polymersomes suspension in water were placed on a carbon 
coated copper grid. After 5 minutes the excess of volume was wicked away with filter paper, the samples 
were negatively stained with 3% uranyl acetate in distilled water and analysed. 191 and 207 individual 
vesicles were measured from the digitised images for mPEGA12a-b-ACH36 and  mPEGA12b-b-CHB36, using 
imageJ 1.45 analysis software. 
 
Atomic Force Microscopy (AFM) 
Atomic Force Microscopy topography images of mPEGA12a-b-ACH36 and mPEGA12a-b-CHB36 polymersomes 
were obtained in liquid at room temperature using a Bruker Icon FastScan Bio operating in PeakForce 
nanomechanical tapping mode in fluid  using ScanA-syst-Fluid+probes (resonant mechanical frequency: 
120– 180 kHz, spring constant: 0.7 N m-1). Images were acquired under ScanAsyst auto control using scan 
rates of 1.60 Hz, with a resolution of 512 x 512 pixels. Small pieces (0.5 cm x 0.5 cm) of freshly cleaved mica 
were used as substrates. 10 mM MgCl2 solution was incubated with cleaved mica for 30 min. Subsequently, 
the mica was washed with distilled water and blow-dried under nitrogen stream at room temperature. 
Polymersomes prepared by the nanoprecipitation method followed by dialysis against PBS were diluted 
with additional PBS to a final polymer concentration of 500 µg mL-1 and filtered through a 0.45 µm syringe 
filter. The diluted polymersome solution (100 µL) was pipetted on the mica substrate and then imaged. 
Image data were analysed using Nanoscope Analysis software (Version 1.5, Bruker). 
 
   
Results and discussion 
In line polymersomes: synthesis of ACH acrylate and CHB acrylamide-based copolymers mPEGA12a-b-
ACH36 and mPEGA12b-b-CHB36. 
Accordingly,  in this work the required monomers were prepared in one step, by DCC-mediated coupling 
reaction of 3-chloro-4-hydroxybenzoic acid with (hydroxyethyl)acrylate (HEA) or (hydroxyethyl)acrylamide 
(HEAM), to give acrylate and acrylamide monomers ACH (2) and CHB (3), respectively (Scheme 1, and  ESI, 
Figure S5-S6, S7-S8). Unlike our previous studies where methacrylates were utilised,35, 36 in this work the 
analogous acrylate/acrylamide monomers, characterised by higher propagation rate coefficient (Kp),37, 38 
required for subsequent one-pot rapid multiple chain extensions at close to full monomer conversion, as 
described by Perrier and co-workers, were synthesised. To prove the versatility of the strategy developed 
in this study, both acrylate and acrylamide monomers were utilised. 
To successfully prepare multiblock copolymers via this one-pot RAFT process, a number of parameters – 
e.g. choice of the solvent, initiator, monomer concentration, temperature and [CTA]/[I] ratio – are key for 
maintaining near-perfect chain-end fidelity, thus ensuring “livingness” of the polymerisation.18  
 
 
 
 
 
 
 
 
 
 
Scheme 1. One-pot RAFT synthesis of amphiphilic mPEGA12a-b-ACH36 and mPEGA12b-b-CHB36 block 
copolymers. Reagents and conditions: a. DCC, DMAP, 16 h, ambient temperature. Solvent: X=O: CH2Cl2. 
X=NH: THF; b. MHP (CTA), VA-044, EtOH/H2O, 70°C. c. X=O: mPEGA12a macro-CTA, ACH monomer, VA-044, 
EtOH/H2O, 70°C; X=NH: mPEGA12b macro-CTA, CHB monomer, VA-044, EtOH/H2O, 70°C.  
  
Table I Characterization and [M]/[CTA]/[I] ratios utilised for the synthesis of mPEGA12 macro-CTAs and 
mPEGA12a-b-ACH36, mPEGA12b-b-CHB36 block copolymers. 
 
A mixture of water/EtOH was chosen as a suitable ”green” solvent39 for the subsequent polymerisation 
step. Water is known to increase the propagation rate coefficient (Kp), and thus the polymerisation rate 
(Rp), of vinyl monomers,40 which is critical for efficient in situ RAFT synthesis of  multiblock copolymers,18  
whilst EtOH was required to solubilise the monomers ACH (2) and CHB (3), and  the (methyl 2-
((((2hydroxyethyl)thio)carbonothioyl)thio)propanoate, (MHP) chain-transfer agent. The latter was chosen 
due to the higher hydrolytic stability of trithiocarbonates compared to other suitable CTAs – e.g. 
dithioesters – and their ability to minimise initial rate retardation sometimes observed in RAFT 
polymerisations.41 In the one-pot protocol optimised in this work a macro-CTA was first synthetised using 
commercially available poly[ethylene glycol(480)] methyl ether acrylate, mPEGA(480) and 2,2'-azobis[2-(2-
imidazolin-2-yl)propane] dihydrochloride (VA-044) as the water soluble initiator [I], at 70°C (Scheme 1). 
VA-044 is characterised by a high decomposition rate (t1/2 2 h at 70°C), which again is key to speeding up 
the polymerisation without losing the chain livingness.32, 33 mPEGA(480) was chosen for the synthesis of 
the first hydrophilic block because of its aqueous solubility, biocompatibility and ability to generate 
polymers with prolonged plasma half-life and low immunogenicity.42-44 After an initial series of experiments 
required to identify suitable reaction conditions (i.e. monomer concentration and [CTA]/[I] molar ratio) 
which would allow to reach near-quantitative monomer conversion whilst retaining chain-end fidelity, a 
[CTA]/[I] ratio of 250:1 and a monomer concentration of 2.0 M were chosen. The degree of polymerisation 
(DP) for the p(mPEGA) macro-CTA was targeted to 12. After 2 h the reaction reached a monomer 
conversion > 95%, as assessed by 1H NMR, by comparing the decrease of the signal for the vinyl proton at 
~ 5.96 ppm to that of the mPEG terminal methoxy group at 3.24 ppm (see ESI, Figure S9-S10). SEC analysis 
of the macro-CTA (mPEG12a, mPEG12b, Table I and Figure 1), using DMF + 0.1% LiBr as the mobile phase 
showed unimodal, symmetric, and narrow molecular weight distributions (Đ < 1.13), with Mn,SEC in good 
agreement with the theoretical one (Table I, polymers 4 and 5). Two different macro-CTAs, mPEGA12a and 
Polymer Code [M]/[CTA]/[I]  Conv%a  Mn,NMR (kDa) Mn,SEC(kDa) Đ 
mPEGA12a 4 12:1:0.004  95  5.7 6.5c 1.05c 
mPEGA12b 5 12:1:0.004  98  5.3 6.1d 1.13d 
mPEGA12a-b-ACH36 6 36:1:0.02  94  15.5b 14.9c 1.18c 
mPEGA12b-b-CHB36 7 36:1:0.034  95  15.2 b 15.1d 1.17d 
aObtained from 1H NMR analysis. bNumber of repeating unit of ACH or CHB monomers, DPACH and DPCHB respectively, were calculated by 1H NMR by comparing 
the integral of monomer aromatic proton peak at 6.93 (I6.93) ppm, and the methoxy peak of mPEGA repeating units at 3.23 ppm (I3.23) set as 3. DPACH (or DPCHB) 
= 12 x  (I6.93 / (I3.23 / 3). Mn,NMR was calculated as: ( DPACH (or DPCHB)x MWmonomer) + MnmacroCTA).  cObtained from SEC analysis in DMF+0.1% LiBr (PMMA standards).  
dObtained from SEC analysis in CHCl3 (polystirene standards).  
   
mPEG12b, both with DP=12 were synthesised and directly utilised without isolation or purification for the 
synthesis of mPEGA12a-b-ACH36 (6) and mPEGA12b-b-CHB36 (7), respectively. Importantly, both reactions led 
to the desired mPEGA12 macro-CTAs with near-quantitative monomer conversion, thus validating the 
reproducibility of this process. Both acrylate ACH (2) and acrylamide CHB (3) monomers have limited 
solubility in water, hence for the second polymerisation step they were first dissolved in EtOH, then the 
resulting solutions were diluted with water to a final EtOH/water volume ratio of 2:1. To ensure full 
monomer conversion in the one-pot RAFT with higher EtOH content, a larger amount of radical intitiator 
was required;33 in this work for the second block a [macro-CTA]/[I] ratio of 150:1 was initially chosen in 
both cases. A DP of 34 for both ACH and CHB was targeted, to provide final copolymers with a hydrophilic 
block weight fraction (f = 35%±10%)45 suitable for self-assembling into vesicles.2 Indeed, when considering 
the Mn provided by 1H NMR analysis the calculated f values were 0.358 and 0.357 for mPEGA12a-b-ACH36 
and mPEGA12b-b-CHB36, respectively. 
Figure 1. SEC traces and 1H NMR spectra (DMSO-d6) of non-purified mPEGA12 macro-CTA and final block 
copolymers for A. mPEGA12a-b-ACH36 (6), and B. mPEGA12b-b-CHB36 (7). 
Following the addition of ACH (2) or CHB (3) monomers and VA-044 radical initiator, a monomer conversion 
of 80-90% was observed after 2 hours. Additional radical initiator was necessary to achieve >95% of 
monomer conversion (Table I, polymer 6 and 7, see ESI Figures S11-S12), resulting in a final [macro-CTA]/[I] 
ratio of 1:50 or 1:30 for mPEGA12a-b-ACH36 and mPEGA12b-b-CHB36, respectively. A possible explanation for 
this is that the second block grown here is longer than most of those prepared by Perrier and coworkers 
for which near-full conversion could be achieved under the conditions reported, 18, 27, 32-34 although other 
side-processes – e.g. very minimal H transfer from ACH (2) or CHB (3) monomers -  cannot in theory be 
ruled out at this stage. Nevertheless, pleasingly, SEC analysis (Table I and Figure 1) showed that very well 
defined block-copolymers with a final Đ of 1.18 (mPEGA12a-b-ACH36) and 1.17 (mPEGA12b-b-CHB36), were 
synthesised indicating good control over the polymerisation process. The DP of the second block was 
determined by 1H NMR, by comparing the integral of the OCH3 signal of mPEGA repeating units in the 
hydrophilic block at 3.24 ppm, with that of the aromatic proton of ACH and CHB repeating units at 6.93 
  
ppm (ESI, Figures S11-S12). A DPNMR of 36 was found for the second block of both mPEGA12a-b-ACH36 (6), 
and mPEGA12b-b-CHB36 (7), slightly higher than the expected 34. This can be explained considering that a 
minimal amount of mPEGA12 macro-CTA was withdrawn at the end of the first polymerisation step for 1H 
NMR and SEC analysis, thus very marginally increasing the monomer:macro-CTA molar ratio.  
Polymersomes in-line assembly, drug loading and characterization. 
At the end of the polymerisation runs the reaction mixtures were diluted with additional EtOH to a polymer 
concentration of 35 mg mL-1 (total volume 37 mL) to facilitate the subsequent manipulations and assembly 
of mPEGA12a-b-ACH36 (6) and mPEGA12b-b-CHB36 (7) into their corresponding polymersomes. The resulting 
solutions were kept at 40°C to ensure full polymer solubilisation and reduced viscosity of the polymer 
solutions. To assemble non drug-loaded vesicles these solutions were directly cannulated under stirring 
into DI water (final polymer concentration of 1 mg mL-1). 
Polymersomes assembly was confirmed by DLS analysis of the water/ethanol mixture immediately after 
the cannulation process. DLS traces showed the presence of nanoassemblies with an average diameter of 
136±2 nm and 89±11 nm for  mPEGA12a-b-ACH36, and mPEGA12b-b-CHB36, respectively.    
Ethanol was removed by either dialysis or slow evaporation at room temperature, and the resulting 
assemblies were characterised by dynamic light scattering (DLS) and transmission electron microscopy 
(TEM). The in line polymersomes assembly process led to homogeneous dispersions of polymeric vesicles 
in water, (Figure 2A), with hydrodynamic diameters estimated by DLS of 122±20 nm or 41±0.18 nm, for 
mPEGA12a-b-ACH36 (6) and mPEGA12b-b-CHB36 (7), respectively, with narrow PDI (<0.23).  Similar results in 
terms of vesicle size and polydispersity were obtained regardless of the method used for removal of traces 
of ethanol in the polymersomes suspension (data not shown).  
To test the efficiency of the in-line process in assembling well-defined vesicles, conventional 
nanoprecipitation of purified mPEGA12a-b-ACH36 (6) and mPEGA12b-b-CHB36 (7) was also performed. 
Accordingly, polymers were dissolved in DMSO (5.0 mg mL-1) and water was added dropwise to the 
resulting solution until a 1.0 mg mL-1 concentration was reached . 
This procedure led to the formation of very similar size vesicles in the case of mPEGA12a-b-ACH36 (122±9 
nm), but larger assemblies in the case of mPEGA12b-b-CHB36 (172±2 nm ESI, Figure S13), a difference that 
could be ascribed to the different procedures and conditions used for their assembly.46  
Analysis of the TEM images performed (ESI Fig. S14 and S15) on polymersomes prepared via the in-line 
procedure and stained with 3% uranyl acetate solution gave results consistent with the size estimated by 
DLS for both mPEGA12a-b-ACH36, with an average core diameter of 126±75 nm, and mPEGA12b-b-CHB36 
(44±5 nm).  
   
To gain further insight into the morphology of these vesicles in solution, mPEGA12a-b-ACH36 and mPEGA12a-
b-CHB36 polymersomes were analysed by AFM in PeakForce tapping mode (Figure 3).  A major advantage 
of this method is that the sample can be imaged in solution, thus obtaing a more realistic representation 
of the vesicles morphology in comparison to microscopy techniques performed on dry samples (i.e. TEM). 
Furthermore, the use of tapping instead of contact mode avoid the flattening caused by the pressure 
exterted, allowing a more accurate estimation of vesicle size and three-dimensional shape. 
 
Figure 2. Characterisation of in-line assembled mPEGA12a-b-ACH36 and mPEGA12b-b-CHB36 polymersomes 
(A) DLS analysis of one representative sample. Size shown refers to distribution of hydrodynamic diameter 
measured by DLS at 173° in water, at 25°C. Size (nm) is reported as z-average mean. N=2.  (B) TEM images 
of polymersomes stained with 3% uranyl acetate solution. 
 
Immobilisation of the polymersomes on the mica surface, a pre-requisite to perform the analysis, was 
achieved by electrostatic interactions.47As described by Li et al.,48 negatively charged polymers can be easily 
immobilized on a mica surface, also negatively charged, via electrostatic interaction mediated by Mg2+. 
Our previous studies35 showed that at physiological conditions (pH 7.4) polymers containing 3-chloro-4-
hydroxybenzoate repeating units are negatively charged due to the deprotonation of part of their aromatic 
alcohol pendant groups. Accordingly, 1.0 mg mL-1 polymersome suspensions were prepared by 
nanoprecipitation in PBS buffer. The average sizes detected were around 80 nm for mPEGA12a-b-ACH36 and 
45 nm for mPEGA12a-b-CHB36 ( Figure 3). The height of both polymeric aggregates was found to be around 
14-17 nm, thus smaller than their diameter, which can be ascribed to a partial collapse of their hollow 
structure, thus confirming their vesicular morphology. 49 Partially collapsed structures with typical ‘deflated’ 
balloon’ morphology could also be visualized (Figure 3, insert 1D), thus further confirming the vesicular 
nature of these supramolecular assemblies.  
  
 
 
 
Figure 3.Representative examples of vesicle morphology as seen by AFM analysis of polymersomes prepared from 
1. mPEGA12a-b-ACH36 and 2. mPEGA12a-b-CHB36. A. AFM height image of polymersomes adsorbed on a mica surface 
in PBS solution (0.50 mg mL-1); B. The corresponding topographic 3D rendered image showing the distribution of 
polymersome heights; C. List of the mean height, mean area and mean diameter of adsorbed polymersomes at 
positions a-e or 1-4. D. Arrows highlight some of the collapsed vesicle structures observed during these 
measurements.  
Larger sizes were estimated by DLS analysis of the polymersomes in PBS (170 and 70 nm for mPEGA12a-b-
ACH36 and mPEGA12a-b-CHB36, respectively, Figure S16 ESI) in comparison to those observed by AFM 
analysis. It has already been shown that the vesicles hydrodynamic diameter estimated by DLS can be larger 
than the geometrical diameter because of the hydration layer of the polymer shell.50 Liang et al. have 
discussed a similar discrepancy observed when analysing EggPC/cholesterol vesicles by both DLS and AFM 
and ascribed it to a potential partial fragmentation of larger vesicle upon adsorption on mica, and/or the 
intrinsic higher sensitivity of DLS for larger vesicle, which results in an overestimation of the mean 
hydrodynamic diameter.51 The latter phenomenon has also been described when AgNPs53 and polystyrene 
nanoparticles 52 were utilised to compare these two analytical techniques.  
   
To establish an automated and robust process to generate polymersomes reproducibly and with very low 
polydispersity, a microfluidic system was then engineered (Figure 4). Indeed, microfluidic strategies have 
been successfully employed to fabricate soft micro- and nano-assemblies54, 55 To this aim, 
polytetrafluoroethylene (PTFE) tubing were secured with gaskets inside the screw-tight caps of a 3-way 
connector. An ethanolic solution (12 mg mL-1) of mPEGA12b-b-CHB36 maintained at 50°C was injected via 
pump syringe at 10 µL min-1 (Flow A, Fig. 4) into a junction where DI water entered via another ID 0.5 mm 
tube at a flow rate of 120 µL min-1 (Flow B, Fig. 4). The mixed liquids (Flow C, Fig. 4) exited the junction via 
an ID 1 mm tube and were collected for size analysis. A range of A and B flow rates were tested in 
preliminary experiments to optimize the solvent mixing inside the connector. Polymersomes were 
obtained with this methodology at a rate of 0.12 mg min-1, and were analysed by DLS before and after 
ethanol evaporation.  
 
Figure 4. Automated assembly of mPEGA12b-b-CHB36 polymersomes:  schematic representation of the  
microfluidic device utilised in this study. 
The average size in the two cases was found to be very similar, with a diameter for the vesicles in pure 
water of 37±7 nm and a PDI of 0.15±0.04. One of the major advantages offered by this technique is the 
possibility of finely tuning the ratio of the two solvents in the device by independently modifying the 
solvent flow rates via syringe pumps, and to minimise the use of organic solvent required to induce the 
formation of homogeneous vesicles. The accurate control of the flow rate also resulted in very consistent 
batch to bacth reproducibility (Figure S17 ESI), in a process that could easily be scaled up for large scale 
production.  
Finally, the efficiency of the in-line assembly process to incorporate  hydrophilic and hydrophobic drugs 
within the vesicle structures was then investigated. In general, therapeutics are entrapped within 
polymersomes either during their preparation, or by introduction of drug molecules into pre-formed 
vesicles.21 For the latter, injection56 or electroporation57 techniques are typically employed. In the former 
case, hydrophobic molecules can be incorporated into polymeric films utilised to prepare polymersomes, 
whilst hydrophilic drugs can be introduced into the aqueous phase used to rehydrate these films.58 Other 
  
commonly used techniques include solvent exchange mediated encapsulation,59 and the use of 
microfluidics to load small molecules or proteins while forming vesicles.60  
In this present study two model molecules, terbinafine, a hydrophobic antifungal drug which is very poorly 
soluble in water in its free base form (< 2 µg mL-1, as assessed by RP-HPLC, data not shown), and hydrophilic 
cyanocobalamine (Vit B12, solubility in water ca. 10-11 mg mL-1)61 were chosen as model drugs for 
incorporation within vesicle lipophilic membrane and aqueous lumen, respectively. In addition to its 
hydrophobic nature, terbinafine was chosen due to the presence of a tertiary alkyl amine in its structure, 
which by forming ionic pairs with the weakly acidic 3-chloro-4-hydroxybenzoic ester repeating units (pKa 
7-7.5)36 in the hydrophobic blocks of mPEGA12a-b-ACH36 and mPEGA12b-b-CHB36 could lead to more efficient 
drug entrapment. This phenomenon was observed in our previous studies using analogous block 
copolymers, where we utilised tamoxifen, a hydrophobic drug with a basic tertiary amine group, which 
gave drug loading capacity as high as 18%.36 In typical experiments, at the end of the polymerisation 
reaction an ethanolic solution of terbinafine free base (35 mg mL-1) was added via syringe to the 
polymerisation mixture to give a 10% w/w drug/polymer solution, at 40 °C. Cyanocobalamine was dissolved 
in the aqueous medium used for the subsequent assembly of mPEGA12a-b-ACH36 (6) and mPEGA12b-b-CHB36 
(7)-based polymersomes, again in a 10% w/w drug/polymer ratio. The polymer-terbinafine solutions were 
then cannulated into water-cyanocobalamine solutions, to generate the desired drug-loaded mPEGA12a-b-
ACH36 and mPEGA12b-b-CHB36-based polymersomes. As observed in previous experiments, rapid self-
assembly into vesicles with no visible precipitation was observed, suggesting that the method was robust, 
and that rapid formation of polymersomes under these conditions was not negatively affected by the 
presence of loaded molecules. The excess of cyanocobalamine was removed by dialysis against water using 
a 6-8 kDa MWCO membrane, while traces of unentrapped terbinafine were subsequently removed after  
 
 
 
 
 
 
 
 
 
 
 
   
the dialysis step by centrifugation, followed by filtration through a 0.45 µm filter. Drug loading was 
quantified by RP-HPLC (see ESI) on the resulting purified vesicles. 
 
Figure 5. (A) Loaded polymersomes (1.0 mg mL-1) size distributions of hydrodynamic diameter measured by DLS at 
173° in water at 25°C. Size (nm) is reported as z-average; (B) terbinafine/cyanocobalamine-loaded mPEGA12a-b-
ACH36 and mPEGA12b-b-CHB36 polymersomes. 
Table 2. Drug loading on vesicles (Loading capacity - LC) and % relative loading (Encapsulation Efficiency - 
EE) of mPEGA12a-b-ACH36 and mPEGA12b-b-CHB36 polymersomes using Cyanocobalamin and Terbinafine as 
model drugs.  
 mPEGA12a-b-ACH36 mPEGA12b-b-CHB36 
drug/pol. wt%a 10 10 
LCcyanocobalamin 3.9±0.4 6.0±0.1 
EEcyanocobalamin 38.7±3.9 51.9±1.0 
LCTerbinafine 2.47±0.03 4.7±2.0 
EETerbinafine 24.7±0.28 46.6±20.4 
aIn the reaction feed before assembly into polymersomes.  
Both mPEGA12a-b-ACH36 and mPEGA12b-b-CHB36, block copolymers displayed a higher cyanocobalamine 
loading capacity (LC) (Table 2).  Interestingly, the acrylamide based polymer mPEGA12b-b-CHB36 showed 
better drug encapsulation for both the hydrophilic cyanocobalamine and lipophilic terbinafine. Vesicles 
were analysed by DLS (Figure 5) to investigate how drug loading affected their size and size distribution. As 
we observed earlier with similar polymers,36 loaded polymersomes showed a smaller hydrodynamic radius 
than the empty assemblies, decreasing to ~ 72 nm for mPEGA12a-b-ACH36 while an increase in size to ~ 80 
nm was observed for mPEGA12b-b-CHB36, as assessed by DLS analysis. 
  
One possible explanation for this phenomenon is a different membrane packing caused by the presence of 
terbinafine and potential ion pairing between the drug and the weakly acidic 3-chloro-4-hydroxybenzoate 
of ACH and 3-chloro-4-hydroxybenzamide of CHB polymer repeating units. The observed high entrapment 
efficiency of cyanocobalamine may be due, at least in part, to additional electrostatic interactions between 
the partially deprotonated 3-chloro-4-hydroxybenzoate/benzamide repeating units and positively charged 
CoIII centres.  
 
Conclusions 
In this study we devised an in line synthetic/assembly strategy which enables facile engineering of drug-
loaded polymersomes in only a few hours, starting from acrylate/acrylamide monomers. Using Perrier’s 
one-pot multiple chain extension RAFT polymerisation strategy, amphiphilic mPEGA12a-b-ACH36 and 
mPEGA12b-b-CHB36 copolymers could be prepared with narrow molecular weight distributions at very high 
monomer conversion. Reaction conditions – concentration of monomers, CTA:radical initiator molar ratio, 
nature of the reaction solvent – were optimised to attain good control over the polymerisation process 
and to avoid intrinsically inefficient purification of reaction intermediates. Importantly, the process was 
developed using ethanol:water as the reaction medium, in view of a potential application of this process 
in biological/biomedical settings. The final reaction mixtures could then be directly utilised to assemble 
well defined polymeric vesicles incorporating both model hydrophilic and hydrophobic drugs in the 
nanocarriers aqueous lumen and hydrophobic membrane, respectively.   
Similarly to click techniques where sub-families of chemical reactions are selected based on a range of 
favourable features, and PISA, where monomers and macromolecular parameters are chosen to direct 
supramolecular assembly, our results suggest that when appropriate reagents and conditions are utilised, 
in line processes could become a viable general route for efficient, scaleable and cost-effective assembly 
of polymersome nanovectors.  
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